Information Provided By:
Fly News Breaks for March 4, 2020
GILD, FTSV
Mar 4, 2020 | 05:09 EDT
Mizuho analyst Mara Goldstein downgraded Forty Seven (FTSV) to Neutral from Buy with a price target of $95.50, up from $53. As the company's bidding process was said to be competitive, a competing takeover to challenge the one from Gilead Sciences (GILD) is unlikely, Goldstein tells investors in a research note. The analyst downgraded Forty Seven to reflect the proposed takeout price.
News For FTSV;GILD From the Last 2 Days
GILD
Sep 22, 2021 | 16:28 EDT
Get caught up quickly on the top news and calls moving stocks with these Top Fives, as compiled by the editors of The Fly. 1... To see the rest of the story go to thefly.com. See Story Here
GILD
Sep 22, 2021 | 13:12 EDT
Get caught up quickly on the top news and calls moving stocks with these Top Fives, as compiled by the editors of The Fly.  1... To see the rest of the story go to thefly.com. See Story Here
GILD
Sep 22, 2021 | 10:11 EDT
Brooklyn ImmunoTherapeutics (BTX) announced the appointment of Roger Sidhu, M.D. as its Chief Medical Officer, effective September 20, 2021. Prior to joining Brooklyn, Dr. Sidhu served as Vice President, Clinical Development at Kite Pharma, a subsidiary of Gilead Sciences (GILD).